All In Biotech

Drug Trial Radar · NCT00377377

Oral Ghrelin Agonist in Healthy Subjects

Pharmacokinetics and Pharmacodynamic Effects of an Oral Ghrelin Agonist in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: May 3, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Nov 2005

Primary completion

Not stated

Study completion Jul 2006

Sponsor

Lead sponsor
University Hospital, Basel, SwitzerlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 18, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

EP01572 is a peptidomimetic growth hormone secretagogue, which has potent GH-releasing activity after intravenous administration.It is an analogue of the natural compound ghrelin. Since an oral delivery system would be preferable in many of the possible therapeutic indications, the pharmacological profile and the GH-releasing activity of increasing single, oral doses of EP01572 in healthy volunteers will be evaluated. In addition, the pharmacokinetics and pharmacological effects of EP01572 will be investigated after intraduodenal administration.

Conditions

  • Healthy Subjects

Interventions

  • EP1572 (ghrelin agonist) oral and duodenal applicationDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Growth hormone release
  2. Pharmacokinetics

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.